본문 바로가기
KERD
논문KCI 등재

Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy

김승업|Park Jun Yong|Lee Hye Won|Kim Do Young|Ahn Sang Hoon|Kim Beom Kyung|Han Kwang-Hyub|Chang Jin Won
거트앤리버 소화기연관학회협의회|2021.01|Gut and Liver|제15권 제1호|pp. 117-127|DOI 10.5009/gnl19301

0

조회

0

다운로드

8

인용

0

참고문헌

키워드

Fatty liverHepatitis BNonalcoholic fatty liver diseaseAntiviral therapyHepatic steatosis index

초록

Background/Aims: The hepatic steatosis index (HSI) is a noninvasive method to assess the severity of hepatic steatosis. Antiviral therapy (AVT) can impact aspartate aminotransferase and alanine aminotransferase levels, which are the main components of the HSI. Thus, we investigated the accuracy of the HSI in detecting hepatic steatosis in patients with chronic hepatitis B (CHB) receiving AVT, compared with those not receiving AVT and in those with nonalcoholic fatty liver disease (NAFLD). Methods: Patients with CHB or NAFLD who underwent a magnetic resonance imaging proton density fat fraction (MRI-PDFF) evaluation between March 2010 and March 2019 were recruited. Hepatic steatosis was diagnosed when the PDFF exceeded 5%. Area under the receiver operating characteristic curve (AUROC) analysis was used to assess the diagnostic accuracy of the HSI in the detection of hepatic steatosis. Results: The mean age of the study population (189 men and 116 women; 244 with CHB [184 with and 60 without AVT] and 61 with NAFLD) was 55.6 years. The AUROC values for detecting hepatic steatosis were similar between patients with CHB (0.727; p<0.001) and those with NAFLD (0.739; p=0.002). However, when patients with CHB were subdivided into those receiving and not receiving AVT, the AUROC value decreased slightly in patients with CHB receiving AVT compared to those without not receiving AVT (0.707; p=0.001 vs 0.779; p=0.001). Conclusions: Despite a slight attenuation, the diagnostic accuracy of the HSI in patients with CHB receiving AVT in detecting hepatic steatosis was still acceptable. Further large-scale studies are required for validation.

Abstract

Background/Aims: The hepatic steatosis index (HSI) is a noninvasive method to assess the severity of hepatic steatosis. Antiviral therapy (AVT) can impact aspartate aminotransferase and alanine aminotransferase levels, which are the main components of the HSI. Thus, we investigated the accuracy of the HSI in detecting hepatic steatosis in patients with chronic hepatitis B (CHB) receiving AVT, compared with those not receiving AVT and in those with nonalcoholic fatty liver disease (NAFLD). Methods: Patients with CHB or NAFLD who underwent a magnetic resonance imaging proton density fat fraction (MRI-PDFF) evaluation between March 2010 and March 2019 were recruited. Hepatic steatosis was diagnosed when the PDFF exceeded 5%. Area under the receiver operating characteristic curve (AUROC) analysis was used to assess the diagnostic accuracy of the HSI in the detection of hepatic steatosis. Results: The mean age of the study population (189 men and 116 women; 244 with CHB [184 with and 60 without AVT] and 61 with NAFLD) was 55.6 years. The AUROC values for detecting hepatic steatosis were similar between patients with CHB (0.727; p<0.001) and those with NAFLD (0.739; p=0.002). However, when patients with CHB were subdivided into those receiving and not receiving AVT, the AUROC value decreased slightly in patients with CHB receiving AVT compared to those without not receiving AVT (0.707; p=0.001 vs 0.779; p=0.001). Conclusions: Despite a slight attenuation, the diagnostic accuracy of the HSI in patients with CHB receiving AVT in detecting hepatic steatosis was still acceptable. Further large-scale studies are required for validation.

참고문헌 (44)

  1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease : meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  2. Loomba R, "The global NAFLD epidemic", Nat Rev Gastroenterol Hepatol, 10, pp.686~690 (2013)
  3. Petta S, "Non-alcoholic fatty liver disease pathogenesis : the present and the future", Dig Liver Dis, 41, pp.615~625 (2009)
  4. Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
  5. Ateş F, "Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B", World J Gastroenterol, 17, pp.4517~4522 (2011)
  6. Negro F, "Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C", J Viral Hepat, 16, pp.681~688 (2009)
  7. Shackel NA, "Liver biopsy: is it still relevant?", Intern Med J, 36, pp.689~691 (2006)
  8. Emanuele E, "Is biopsy always necessary? Toward a clinicolaboratory approach for diagnosing nonalcoholic steatohepatitis in obesity", Hepatology, 48, pp.2086~2087 (2008)
  9. Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
  10. Hernaez R, "Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver : a meta-analysis", Hepatology, 54, pp.1082~1090 (2011)
  11. Schwenzer NF, "Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance", J Hepatol, 51, pp.433~445 (2009)
  12. Reeder SB, "Proton density fat-fraction : a standardized MR-based biomarker of tissue fat concentration", J Magn Reson Imaging, 36, pp.1011~1014 (2012)
  13. Reeder SB, "Quantification of hepatic steatosis with MRI : the effects of accurate fat spectral modeling", J Magn Reson Imaging, 29, pp.1332~1339 (2009)
  14. Springer F, "Liver fat content determined by magnetic resonance imaging and spectroscopy", World J Gastroenterol, 16, pp.1560~1566 (2010)
  15. Reeder SB, "Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy", J Magn Reson Imaging, 34, pp.729~749 (2011)
  16. Zhang Z, "Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection", Sci Rep, 6, pp.32875~ (2016)
  17. Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
  18. Xu L, "A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B", Dig Liver Dis, 49, pp.910~917 (2017)
  19. Elwan N, "Study of hepatic steatosis index in patients with chronic HCV infection", Int J Curr Microbiol App Sci, 5, pp.266~274 (2016)
  20. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Hepatology, 55, pp.2005~2023 (2012)
  21. Puri P, "Nonalcoholic fatty liver disease: definitions, risk factors, and workup", Clin Liver Dis(Hoboken), 1, pp.99~103 (2012)
  22. Caussy C, "Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis", Hepatology, 67, pp.1348~1359 (2018)
  23. Gaiani S, "What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy", J Hepatol, 27, pp.979~985 (1997)
  24. Di Lelio A, "Cirrhosis : diagnosis with sonographic study of the liver surface", Radiology, 172, pp.389~392 (1989)
  25. Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
  26. Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)
  27. Castéra L, "Pain experienced during percutaneous liver biopsy", Hepatology, 30, pp.1529~1530 (1999)
  28. Hamaguchi M, "The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation", Am J Gastroenterol, 102, pp.2708~2715 (2007)
  29. Duman DG, "Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment?", Dig Dis Sci, 51, pp.346~351 (2006)
  30. Lee SW, "Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors : comparison of visual grading with liver attenuation index", Radiology, 244, pp.479~485 (2007)
  31. Fishbein MH, "Introduction of fast MR imaging in the assessment of hepatic steatosis", Magn Reson Imaging, 15, pp.287~293 (1997)
  32. Jin X, "Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B", PLoS One, 7, pp.e34198~ (2012)
  33. David Sooik Kim, "Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir", Clinical and Molecular Hepatology, 25(3), pp.283~293 (2019), 대한간학회
  34. Han E, "Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B", Aliment Pharmacol Ther, 48, pp.300~312 (2018)
  35. Tada T, "Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis : comparison with MRI-determined proton density fat fraction", AJR Am J Roentgenol, 212, pp.332~341 (2019)
  36. Haufe WM, "Accuracy of PDFF estimation by magnitude-based and complex-based MRI in children with MR spectroscopy as a reference", J Magn Reson Imaging, 46, pp.1641~1647 (2017)
  37. Fang KC, "Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis", J Chin Med Assoc, 80, pp.125~132 (2017)
  38. Cao W, "Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis", PLoS One, 8, pp.e82092~ (2013)
  39. van der Poorten D, "Hepatic fat loss in advanced nonalcoholic steatohepatitis:are alterations in serum adiponectin the cause?", Hepatology, 57, pp.2180~2188 (2013)
  40. Chauhan A, "Platelets : no longer bystanders in liver disease", Hepatology, 64, pp.1774~1784 (2016)
  41. Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials", Hepatology, 58, pp.1930~1940 (2013)
  42. Reeder SB, "Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis", Hepatology, 58, pp.1877~1880 (2013)
  43. Jeong-Ju Yoo, "Recent research trends and updates on nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 25(1), pp.1~11 (2019), 대한간학회
  44. An C, "Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance(MIRACLEHCC) : study protocol for a prospective randomized trial", BMC Cancer, 18, pp.915~ (2018)

이 간행물의 다른 논문 (17건)

Fecal Microbiota Transplantation Is Effective for the Treatment of Partially Treated Clostridioides difficile InfectionCho Young-Seokpp. 1-2Precision Medicine Approaches to Prevent Gastric CancerJuntaro Matsuzaki, Hitoshi Tsugawa, Hidekazu Suzukipp. 3-12Helicobacter pylori Treatment Strategies in SingaporeTiing-Leong Ang, Daphne Angpp. 13-18Expanding Indications for Liver Transplant: Tumor and Patient FactorsChu Kevin Ka-Wan, Chok Kenneth Siu-Ho, Wong Kelly Hiu-Chingpp. 19-30Molecular Features of the Serrated Pathway to Colorectal Cancer: Current Knowledge and Future DirectionsBustamante-Balén Marco, Satorres Carla, García-Campos Maríapp. 31-43
원문 보기